This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017:2017:2309574.

doi: 10.1155/2017/2309574. Epub 2017 Jan 4.

The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections 2016

Roberta Rizzo¹, Enrico Fainardi², Nathalie Rouas-Freiss³, Fabio Morandi⁴

Affiliations

Affiliations

¹ Department of Experimental and Diagnostic Medicine, Section of Microbiology, University of Ferrara, Ferrara, Italy.
² Neuroradiology Unit, Department of Diagnostic Imaging, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
³ CEA, Institut des Maladies Emergentes et des Thérapies Innovantes (iMETI), Service de Recherches en Hémato-Immunologie (SRHI), Hôpital Saint-Louis, Paris, France.
⁴ Laboratory of Oncology, G. Gaslini Scientific Institute, Genoa, Italy.

PMID: 28133618
PMCID: PMC5241481
DOI: 10.1155/2017/2309574

Editorial

The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections 2016

Roberta Rizzo et al. J Immunol Res. 2017.

. 2017:2017:2309574.

doi: 10.1155/2017/2309574. Epub 2017 Jan 4.

Authors

Roberta Rizzo¹, Enrico Fainardi², Nathalie Rouas-Freiss³, Fabio Morandi⁴

Affiliations

¹ Department of Experimental and Diagnostic Medicine, Section of Microbiology, University of Ferrara, Ferrara, Italy.
² Neuroradiology Unit, Department of Diagnostic Imaging, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
³ CEA, Institut des Maladies Emergentes et des Thérapies Innovantes (iMETI), Service de Recherches en Hémato-Immunologie (SRHI), Hôpital Saint-Louis, Paris, France.
⁴ Laboratory of Oncology, G. Gaslini Scientific Institute, Genoa, Italy.

PMID: 28133618
PMCID: PMC5241481
DOI: 10.1155/2017/2309574

No abstract available

PubMed Disclaimer

Similar articles

HLA-G and MIC expression in tumors and their role in anti-tumor immunity.
Seliger B, Abken H, Ferrone S. Seliger B, et al. Trends Immunol. 2003 Feb;24(2):82-7. doi: 10.1016/s1471-4906(02)00039-x. Trends Immunol. 2003. PMID: 12547505 Review.
HLA-G: on the track of immunological functions.
Le Bouteiller P. Le Bouteiller P. Eur J Immunogenet. 1997 Oct;24(5):397-408. doi: 10.1046/j.1365-2370.1997.d01-109.x. Eur J Immunogenet. 1997. PMID: 9442807 Review. No abstract available.
Non-classical HLA-G antigen and its role in the cancer progression.
Tripathi P, Agrawal S. Tripathi P, et al. Cancer Invest. 2006 Mar;24(2):178-86. doi: 10.1080/07357900500524579. Cancer Invest. 2006. PMID: 16537188 Review.
HLA-G and cancer.
Carosella ED, Horuzsko A. Carosella ED, et al. Semin Cancer Biol. 2007 Dec;17(6):411-2. doi: 10.1016/j.semcancer.2007.06.014. Epub 2007 Jul 10. Semin Cancer Biol. 2007. PMID: 17698367 No abstract available.
Capacity of myeloid and plasmacytoid dendritic cells especially at mature stage to express and secrete HLA-G molecules.
Le Friec G, Gros F, Sebti Y, Guilloux V, Pangault C, Fauchet R, Amiot L. Le Friec G, et al. J Leukoc Biol. 2004 Dec;76(6):1125-33. doi: 10.1189/jlb.0104015. Epub 2004 Aug 26. J Leukoc Biol. 2004. PMID: 15331623

See all similar articles

Cited by

Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S, Paz-Ares L, Herbst RS, Reck M. Peters S, et al. J Immunother Cancer. 2022 Jul;10(7):e004863. doi: 10.1136/jitc-2022-004863. J Immunother Cancer. 2022. PMID: 35858709 Free PMC article. Review.
What Inhibits Natural Killers' Performance in Tumour.
Papak I, Chruściel E, Dziubek K, Kurkowiak M, Urban-Wójciuk Z, Marjański T, Rzyman W, Marek-Trzonkowska N. Papak I, et al. Int J Mol Sci. 2022 Jun 24;23(13):7030. doi: 10.3390/ijms23137030. Int J Mol Sci. 2022. PMID: 35806034 Free PMC article. Review.
Targeting of Non-Classical Human Leukocyte Antigens as Novel Therapeutic Strategies in Cancer.
Benitez Fuentes JD, Bartolome Arcilla J, Mohamed Mohamed K, Lopez de Sa A, de Luna Aguilar A, Guevara-Hoyer K, Ballestin Martinez P, Lazaro Sanchez AD, Carosella ED, Ocaña A, Sánchez-Ramon S. Benitez Fuentes JD, et al. Cancers (Basel). 2024 Dec 22;16(24):4266. doi: 10.3390/cancers16244266. Cancers (Basel). 2024. PMID: 39766165 Free PMC article. Review.
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Dhatchinamoorthy K, Colbert JD, Rock KL. Dhatchinamoorthy K, et al. Front Immunol. 2021 Mar 9;12:636568. doi: 10.3389/fimmu.2021.636568. eCollection 2021. Front Immunol. 2021. PMID: 33767702 Free PMC article. Review.
Increased sHLA-G Is Associated with Improved COVID-19 Outcome and Reduced Neutrophil Adhesion.
Bortolotti D, Gentili V, Rizzo S, Schiuma G, Beltrami S, Spadaro S, Strazzabosco G, Campo G, Carosella ED, Papi A, Rizzo R, Contoli M. Bortolotti D, et al. Viruses. 2021 Sep 17;13(9):1855. doi: 10.3390/v13091855. Viruses. 2021. PMID: 34578436 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program